--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About CTMX20260417C5
Pharmaceutical
CytomX Therapeutics, Inc., was incorporated in Delaware in September 2010 and its operations began in 2008. The Company is a clinical-stage, oncology-focused biopharmaceutical company developing innovative therapies based on its proprietary PROBODY technology platform. The platform enables conditionally activated biologics designed to selectively target tumors, and its state-of-the-art clinical program, Varseta-M, is an antibody-drug conjugate in Phase 1 development for colorectal cancer.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
